After earnings plunge, BioNTech pins hopes on cancer drug launches

Germany's BioNTech, whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, reported on Wednesday a plunge in 2023 revenue and earnings as its focus shifts towards cancer drug development. The Mainz-based company posted revenues of 3.819 billion euros ($4.14…#pfizer #partnerpfizer
Source: Reuters: Health - Category: Consumer Health News Source Type: news